Elsevier

Experimental Neurology

Volume 177, Issue 1, September 2002, Pages 183-192
Experimental Neurology

Regular Article
Role of TNF-α Receptors in Mice Intoxicated with the Parkinsonian Toxin MPTP

https://doi.org/10.1006/exnr.2002.7960Get rights and content

Abstract

The loss of dopaminergic neurons in Parkinson's disease is associated with a glial reaction and the overproduction of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α). TNF-α acts via two different receptors, TNFR1 and TNFR2, and is believed to have both a neuroprotective and a deleterious role for neurons. In order to analyze the putative role of TNF-α in parkinsonism, we compared the effect of the parkinsonian drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice lacking TNFR1, TNFR2, or both receptors and in wild-type littermates. We show that MPTP does not affect spontaneous activity or anxiety in any of the groups and that it reduces motor activity on a rotarod in double knock out mice but not in mice lacking only one receptor. Postmortem analysis revealed no differences in the number of nigral dopaminergic neurons whatever the group. In contrast, striatal dopamine level was slightly decreased in double knock-out mice and more reduced by MPTP in this group than in the other groups of mice. In addition, dopamine turnover was significantly more increased in double knock out mice after MPTP injection. These data suggest that TNF-α does not participate in the death of dopaminergic neurons in parkinsonism but that it slightly alters dopamine metabolism or the survival of dopaminergic terminals by a mechanism involving both receptors.

References (83)

  • K.K. Hale et al.

    Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors

    Cytokine.

    (1995)
  • T. Hama et al.

    Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures

    Neuroscience

    (1991)
  • K. Hamre et al.

    Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: Quantitative analysis in seven strains of Mus musculus

    Brain Res.

    (1999)
  • J.A. Hoskins et al.

    The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice

    Neuropharmacology

    (1989)
  • L.F. Jarskog et al.

    Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro

    Int. J. Dev. Neurosci.

    (1997)
  • A. Kalb et al.

    Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics

    J. Biol. Chem.

    (1996)
  • I. Kurkowska-Jastrzebska et al.

    The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse

    Exp. Neurol.

    (1999)
  • M.P. Mattson et al.

    Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease

    Brain Res. Brain Res. Rev.

    (1997)
  • P.L. McGeer et al.

    The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases

    Brain Res. Brain Res. Rev.

    (1995)
  • S.O. McGuire et al.

    Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons

    Exp. Neurol.

    (2001)
  • J.E. Merrill et al.

    Cytokines in inflammatory brain lesions: Helpful and harmful

    Trends Neurosci.

    (1996)
  • M. Mogi et al.

    Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease

    Neurosci. Lett.

    (1995)
  • M. Mogi et al.

    Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients

    Neurosci. Lett.

    (1994)
  • M. Mogi et al.

    Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease

    Neurosci. Lett.

    (1996)
  • M. Mogi et al.

    Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

    Neurosci. Lett.

    (1994)
  • M. Mogi et al.

    Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum

    Neurosci. Lett.

    (1998)
  • M. Mogi et al.

    Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-alpha induction

    Neurosci. Lett.

    (1999)
  • N.J. Rothwell et al.

    Cytokines in neurodegeneration and repair

    Int. J. Dev. Neurosci.

    (1995)
  • G. Rozas et al.

    Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test

    Brain Res.

    (1997)
  • K. Shinpo et al.

    Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons

    Brain Res.

    (1999)
  • E. Shohami et al.

    Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant

    J. Neuroimmunol.

    (1997)
  • M. Tamatani et al.

    Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons

    J. Biol. Chem.

    (1999)
  • J.K. Westwick et al.

    Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase

    J. Biol. Chem.

    (1994)
  • E. Appel et al.

    Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli

    Neuroreport

    (1997)
  • S.W. Barger et al.

    Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: Evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation

    Proc. Natl. Acad. Sci. USA

    (1995)
  • B. Beutler et al.

    Tumor necrosis, cachexia, shock, and inflammation: A common mediator

    Annu. Rev. Biochem.

    (1988)
  • L.M. Bolin et al.

    Increased vulnerability of dopaminergic neurons in MPTP-lesioned IL-6 KO mice

    Soc. Neurosci. Abstr.

    (2001)
  • D.A. Brenner et al.

    Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha

    Nature

    (1989)
  • A.J. Bruce et al.

    Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors

    Nat. Med.

    (1996)
  • F. Cambi et al.

    5′ flanking DNA sequences direct cell-specific expression of rat tyrosine hydroxylase

    J. Neurochem.

    (1989)
  • E.A. Carswell et al.

    An endotoxin-induced serum factor that causes necrosis of tumors

    Proc. Natl. Acad. Sci. USA

    (1975)
  • Cited by (81)

    • TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects

      2015, Neuroscience
      Citation Excerpt :

      TNFR-mediated neuroprotection is not limited to conditions of acute ischemic injury. In a mouse model for PD, induced by peripheral injection of mitochondrial complex 1 inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), mice deficient in both TNFR, but not individual receptors, showed reduced dopamine levels before and after acute MPTP intoxication compared to controls although numbers of nigral dopaminergic neurons were not altered (Rousselet et al., 2002). In another study, acute MPTP intoxication increased neuronal damage in the hippocampus of double TNFR-deficient mice, pointing to a combined neuroprotective effect of the two TNFR (Sriram et al., 2006).

    • Methods and Models of the Nonmotor Symptoms of Parkinson Disease

      2015, Movement Disorders: Genetics and Models: Second Edition
    • The effect of dopamine on MPTP-induced rotarod disability

      2013, Neuroscience Letters
      Citation Excerpt :

      Some reports have shown rotarod disability 3 days after MPTP administration [25], while others show no difference [23]. Similarly, conflicting reports are observed at 7 days post-lesion [1,17,20]. Impairment is consistently observed 40 days or more post-lesion [11,21].

    View all citing articles on Scopus
    View full text